Maxcyte annual return on equity
2020
2021
2022
2023
2024
2025
Maxcyte Return on Equity (ROE) Growth & History (MXCT)
Maxcyte's return on equity was −23.63% for fiscal 2025.
View full Maxcyte company overviewMaxcyte annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −23.63% | −4.90 pp |
| 2024 | 2024-12-31 | −18.73% | −3.13 pp |
| 2023 | 2023-12-31 | −15.60% | −6.48 pp |
| 2022 | 2022-12-31 | −9.12% | +3.77 pp |
| 2021 | 2021-12-31 | −12.89% | +37.58 pp |
| 2020 | 2020-12-31 | −50.47% | — |
Maxcyte quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5.43% | +0.90 pp |
| Q1 2026 | 2026-03-31 | −2.80% | +2.26 pp |
| Q4 2025 | 2025-12-31 | −5.46% | −0.40 pp |
| Q3 2025 | 2025-09-30 | −6.69% | −1.37 pp |
| Q2 2025 | 2025-06-30 | −6.33% | −2.15 pp |
| Q1 2025 | 2025-03-31 | −5.06% | −0.90 pp |
| Q4 2024 | 2024-12-31 | −5.05% | −2.78 pp |
| Q3 2024 | 2024-09-30 | −5.32% | −0.58 pp |
| Q2 2024 | 2024-06-30 | −4.19% | +0.11 pp |
| Q1 2024 | 2024-03-31 | −4.16% | +0.18 pp |
| Q4 2023 | 2023-12-31 | −2.27% | −0.38 pp |
| Q3 2023 | 2023-09-30 | −4.74% | −2.23 pp |
| Q2 2023 | 2023-06-30 | −4.30% | −1.12 pp |
| Q1 2023 | 2023-03-31 | −4.34% | −2.79 pp |
| Q4 2022 | 2022-12-31 | −1.89% | −0.04 pp |
| Q3 2022 | 2022-09-30 | −2.51% | −0.95 pp |
| Q2 2022 | 2022-06-30 | −3.18% | +4.71 pp |
| Q1 2022 | 2022-03-31 | −1.55% | — |
| Q4 2021 | 2021-12-31 | −1.85% | — |
| Q3 2021 | 2021-09-30 | −1.56% | — |
| Q2 2021 | 2021-06-30 | −7.89% | — |
Maxcyte return on equity trends
Over the last five fiscal years, Maxcyte's return on equity increased from −50.47% to −23.63%, a change of +26.84 percentage points. The latest reported quarter, Q2 2026, shows −5.43%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maxcyte source filings ↗